| 摘要 |
Polysulfonic acid compounds shown by formula (1) or (2) or pharmaceutically acceptable salts thereof exhibit an in vivo antitumor effect on rat prostatic cancer and an antiangiogenic activity by the rat aorta ring assay and the rabbit corneal assay. The compounds are thus expected to be useful as antitumor and angiogenic inhibitors. In formula (1) and (2) M, X, X1, X2, Y1, Y2 and Z represent a specific group, respectively. |
